In short
- Revenue for the cumulative third quarter was ¥406 million, up 10.0% year on year.
- Operating loss was ¥736 million, narrowing by ¥68 million from the same period of the previous fiscal year.
- Patient enrollment was completed for CBA-1205 in patients with hepatocellular carcinoma and melanoma, and a collaborative research agreement was signed with FRONTEO for DoppeLib®.
What they reported
this period against the same period a year earlier, and where they now expect the year to endSales
| Period | ¥m |
|---|---|
| FY24/12 Q1 | 129.0 |
| FY24/12 Q2 | 134.0 |
| FY24/12 Q3 | 159.0 |
| FY24/12 Q4 | 358.0 |
| FY25/12 Q1 | 138.0 |
| FY25/12 Q2 | 113.0 |
| FY25/12 Q3 | 118.0 |
| FY25/12 Q4 | 224.0 |
| FY26/12 Q1 | 147.0 |
| FY26/12 Q2 | 126.0 |
| FY26/12 Q3 | 133.0 |
Revenue related to biosimilars increased in the drug discovery support business.
製薬企業向けの研究支援の売上高が減少・バイオシミラー関連の売上高が拡大Revenue from the drug discovery support business increased 10.0% year on year.
2026年12月期3Qの売上高は406百万円。前年同期比10.0%の増収。Operating profit
| Period | ¥m |
|---|---|
| FY24/12 Q1 | -322.0 |
| FY24/12 Q2 | -259.0 |
| FY24/12 Q3 | -339.0 |
| FY24/12 Q4 | -110.0 |
| FY25/12 Q1 | -264.0 |
| FY25/12 Q2 | -272.0 |
| FY25/12 Q3 | -269.0 |
| FY25/12 Q4 | -174.0 |
| FY26/12 Q1 | -232.0 |
| FY26/12 Q2 | -247.0 |
| FY26/12 Q3 | -257.0 |
Research and development expenses and other costs declined.
臨床開発関連費用等の減少Ordinary profit
| Period | ¥m |
|---|---|
| FY24/12 Q1 | -303.0 |
| FY24/12 Q2 | -260.0 |
| FY24/12 Q3 | -351.0 |
| FY24/12 Q4 | -105.0 |
| FY25/12 Q1 | -265.0 |
| FY25/12 Q2 | -274.0 |
| FY25/12 Q3 | -268.0 |
| FY25/12 Q4 | -182.0 |
| FY26/12 Q1 | -232.0 |
| FY26/12 Q2 | -249.0 |
| FY26/12 Q3 | -256.0 |
Net profit
| Period | ¥m |
|---|---|
| FY24/12 Q1 | -304.0 |
| FY24/12 Q2 | -259.0 |
| FY24/12 Q3 | -352.0 |
| FY24/12 Q4 | -105.0 |
| FY25/12 Q1 | -266.0 |
| FY25/12 Q2 | -274.0 |
| FY25/12 Q3 | -260.0 |
| FY25/12 Q4 | -182.0 |
| FY26/12 Q1 | -233.0 |
| FY26/12 Q2 | -250.0 |
| FY26/12 Q3 | -256.0 |
Their own numbers
figures this company chose to report, a year ago against nowAs of 30 September 2026, the company had 63 employees.
Doses of up to 30 mg/kg were administered in the first part, confirming a high level of safety.
A total of 22 people are included in the table of adverse events related to CBA-1205.
The low–high ranges are Komori's estimate, not figures the company gave.
Everything else in the deck
By business
New initiatives
- In September 2026, a collaborative research agreement was signed with FRONTEO to develop bispecific antibody therapeutics using DoppeLib®.
- Alfresa HD, キッズウェル, Mycenax and the company are jointly advancing the development of domestic manufacturing facilities for biopharmaceuticals.
- Patient enrollment and dosing are underway in the pediatric cancer arm of CBA-1205.
- The monotherapy arm of CBA-1535 has been extended to expand the clinical data ahead of out-licensing.
What decks usually leave out
COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deckMargins and overheads
Overheads (selling and admin costs): ¥1.1bn
Financial targets
| Period | % |
|---|---|
| FY21/12 | -59.1 |
| FY22/12 | -67.4 |
| FY23/12 | -82.8 |
| FY24/12 | -66.3 |
| FY25/12 | -64.6 |
| Period | % |
|---|---|
| FY21/12 | 79.4 |
| FY22/12 | 80.2 |
| FY23/12 | 65.1 |
| FY24/12 | 77.4 |
| FY25/12 | 64.1 |
| FY26/12 | 82.0 |
Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.